bispecific BiTE antibodies (DART, cancer), MacroGenics/Pfizer

N/A

Report date: 2026/03/19 16:59:37

Base Information

Drug Namebispecific BiTE antibodies (DART, cancer), MacroGenics/Pfizer
Drug Alias NameCD19xCD3 DARTCD19xTCR DARTanti-TCR/anti-CD19 bispecific T-cell engager (MacroGenics/Pfizer)anti-CD3/anti-CD19 bispecific T-cell engager (MacroGenics/Pfizer)EGFRxIGF1R IgDART
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT-cell receptor modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3T-cell receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncMacrogenics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A